MedTrace Logo

Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure

NCT05959421 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-04-24

No results posted yet for this study

Summary

This study is a multi-center, open label, randomized phase 3b trial to assess the durability of Immunity induced by the Ebolavirus Vaccine VSV-EBOV ( with or without booster vaccination) in individuals at potential occupational risk for ebolavirus exposure

Conditions

  • Ebola Vaccine

Interventions

BIOLOGICAL

ERVEBO® (rVSV∆G-ZEBOV-GP)

intramuscular vaccination

BIOLOGICAL

ERVEBO® (rVSV∆G-ZEBOV-GP)

intramuscular vaccination

Sponsors & Collaborators

  • Bernhard Nocht Institute for Tropical Medicine

    collaborator OTHER_GOV

  • Goethe University

    collaborator OTHER

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV

  • Monipol Deutschland GmbH

    collaborator UNKNOWN

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Marylyn M Addo, Prof · Universitätsklinikum Hamburg-Eppendorf

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-12-31
Completion
2028-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05959421 on ClinicalTrials.gov